Literature DB >> 862648

Proscillaridin activity in portal and peripheral venous blood after oral administration to man.

K E Andersson, B Bergdahl, H Dencker, G Wettrell.   

Abstract

The absorption of proscillaridin A was studied in four patients undergoing catheterization of the portal vein for diagnostic purposes. Proscillaridin 1.5 mg was given as a single oral dose and plasma glycoside activity was analyzed by the 86Rb-uptake inhibition technique. Proscillaridin appeared rapidly in the portal blood, peak activity being found after 15 min in three and after 30 min in one patient. In peripheral blood the peak activity occurred after approximately 35 min. Despite rapid passage across the gut wall, porto-peripheral differences in glycoside activity were small; they were zero after 4h. The mean amount absorbed as active porscillaridin during the first 4h after the dose was calculated to be only 7.1% of the given amount. Late porto-peripheral differences, probably due to enterohepatic recycling, appeared after 6h in three patients; The results suggest that proscillaridin undergoes first pass inactivation in the gut wall. Enterohepatic recirculation may contribute to the amounts of active glycoside that reach the systemic circulation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 862648     DOI: 10.1007/bf00607677

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  In vitro stability of proscillaridin A.

Authors:  K E Andersson; A Bertler; A Redfors
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

Review 2.  Metabolism of hormones, drugs and other substances by the gut.

Authors:  K Hartiala
Journal:  Physiol Rev       Date:  1973-04       Impact factor: 37.312

3.  [Intestinal absorption of cardiac glycosides in vitro and in vivo].

Authors:  W Forth; E Furukawa; W Rummel
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1969

4.  [Plasma levels, elimination and cumulation of proscillaridin in renal failure (author's transl)].

Authors:  G G Belz; W J Brech
Journal:  Klin Wochenschr       Date:  1974-07-01

5.  [Clinical experimental studies with the heart glycoside, proscillaridin, with special reference to its enteral resorption rate].

Authors:  G G Belz
Journal:  Med Klin       Date:  1968-01-19

6.  An improved method of estimating digoxin in human plasma.

Authors:  A Bertler; A Redfors
Journal:  Clin Pharmacol Ther       Date:  1970 Sep-Oct       Impact factor: 6.875

7.  [Therapeutic experiences with a new cardiac glycoside: proscillaridin A].

Authors:  G Meier; G Wagner
Journal:  Med Welt       Date:  1965-08-28

8.  On the pharmacokinetics of proscillaridin A in man.

Authors:  K E Andersson; A Bertler; A Redfors
Journal:  Eur J Clin Pharmacol       Date:  1975-08-14       Impact factor: 2.953

9.  Absorption of digoxin in man after oral and intrasigmoid administration studied by portal vein catheterization.

Authors:  K E Andersson; L Nyberg; H Dencker; J Göthlin
Journal:  Eur J Clin Pharmacol       Date:  1975-10-10       Impact factor: 2.953

10.  Metabolism and excretion of methylproscillaridin by man.

Authors:  N Rietbrock; R Staud
Journal:  Eur J Clin Pharmacol       Date:  1975-08-14       Impact factor: 2.953

View more
  4 in total

1.  Biliary excretion and enterochepatic recycling of proscillaridin A after oral adminstration to man.

Authors:  K E Andersson; B Bergdahl; G Wettrell
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

2.  Stability in vitro of methylproscillaridin.

Authors:  B Bergdahl; K E Andersson
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

3.  The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans.

Authors:  D J Back; A M Breckenridge; M MacIver; M Orme; H S Purba; P H Rowe; I Taylor
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

Review 4.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.